Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer

Takahiro Yoshioka, Kazuhiko Shien, Kei Namba, Hidejiro Torigoe, Hiroki Sato, Shuta Tomida, Hiromasa Yamamoto, Hiroaki Asano, Junichi Sou, Kazunori Tsukuda, Takeshi Nagasaka, Toshiyoshi Fujiwara, Shinichi Toyooka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti-human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti-HER2 drug presently available for gastric cancer. In this study, we propose novel treatment options for patients with HER2-positive gastric cancer. First, we determined the molecular profiles of 12 gastric cancer cell lines, and examined the antitumor effect of the pan-HER inhibitors afatinib and neratinib in those cell lines. Additionally, we analyzed HER2 alteration in 123 primary gastric cancers resected from Japanese patients to clarify possible candidates with the potential to respond to these drugs. In the drug sensitivity analysis, both afatinib and neratinib produced an antitumor effect in most of the HER2-amplified cell lines. However, some cells were not sensitive to the drugs. When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors. A combination therapy consisting of pan-HER inhibitors and an IGF-1R inhibitor, picropodophyllin, showed a notable synergistic effect. Among 123 clinical samples, we found 19 cases of HER2 amplification and three cases of oncogenic mutations. In conclusion, afatinib and neratinib are promising therapeutic options for the treatment of HER2-amplified gastric cancer. In addition to HER2 amplification, IGFBP7 might be a biomarker of sensitivity to these drugs, and IGF-1R-targeting therapy can overcome drug insensitiveness in HER2-amplified gastric cancer.

Original languageEnglish
Pages (from-to)1166-1176
Number of pages11
JournalCancer Science
Volume109
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Stomach Neoplasms
Somatomedin Receptors
Pharmaceutical Preparations
Cell Line
Therapeutics
human ERBB2 protein
Tumor Suppressor Genes
Transcriptional Activation
Neoplasms
Biomarkers
Messenger RNA
Mutation
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
BIBW 2992

Keywords

  • Afatinib
  • gastric cancer
  • HER2
  • IGFBP7
  • neratinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. / Yoshioka, Takahiro; Shien, Kazuhiko; Namba, Kei; Torigoe, Hidejiro; Sato, Hiroki; Tomida, Shuta; Yamamoto, Hiromasa; Asano, Hiroaki; Sou, Junichi; Tsukuda, Kazunori; Nagasaka, Takeshi; Fujiwara, Toshiyoshi; Toyooka, Shinichi.

In: Cancer Science, Vol. 109, No. 4, 01.04.2018, p. 1166-1176.

Research output: Contribution to journalArticle

Yoshioka, Takahiro ; Shien, Kazuhiko ; Namba, Kei ; Torigoe, Hidejiro ; Sato, Hiroki ; Tomida, Shuta ; Yamamoto, Hiromasa ; Asano, Hiroaki ; Sou, Junichi ; Tsukuda, Kazunori ; Nagasaka, Takeshi ; Fujiwara, Toshiyoshi ; Toyooka, Shinichi. / Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. In: Cancer Science. 2018 ; Vol. 109, No. 4. pp. 1166-1176.
@article{4f6bed99a5794928bd4d3082f691f300,
title = "Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer",
abstract = "Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti-human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti-HER2 drug presently available for gastric cancer. In this study, we propose novel treatment options for patients with HER2-positive gastric cancer. First, we determined the molecular profiles of 12 gastric cancer cell lines, and examined the antitumor effect of the pan-HER inhibitors afatinib and neratinib in those cell lines. Additionally, we analyzed HER2 alteration in 123 primary gastric cancers resected from Japanese patients to clarify possible candidates with the potential to respond to these drugs. In the drug sensitivity analysis, both afatinib and neratinib produced an antitumor effect in most of the HER2-amplified cell lines. However, some cells were not sensitive to the drugs. When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors. A combination therapy consisting of pan-HER inhibitors and an IGF-1R inhibitor, picropodophyllin, showed a notable synergistic effect. Among 123 clinical samples, we found 19 cases of HER2 amplification and three cases of oncogenic mutations. In conclusion, afatinib and neratinib are promising therapeutic options for the treatment of HER2-amplified gastric cancer. In addition to HER2 amplification, IGFBP7 might be a biomarker of sensitivity to these drugs, and IGF-1R-targeting therapy can overcome drug insensitiveness in HER2-amplified gastric cancer.",
keywords = "Afatinib, gastric cancer, HER2, IGFBP7, neratinib",
author = "Takahiro Yoshioka and Kazuhiko Shien and Kei Namba and Hidejiro Torigoe and Hiroki Sato and Shuta Tomida and Hiromasa Yamamoto and Hiroaki Asano and Junichi Sou and Kazunori Tsukuda and Takeshi Nagasaka and Toshiyoshi Fujiwara and Shinichi Toyooka",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/cas.13546",
language = "English",
volume = "109",
pages = "1166--1176",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer

AU - Yoshioka, Takahiro

AU - Shien, Kazuhiko

AU - Namba, Kei

AU - Torigoe, Hidejiro

AU - Sato, Hiroki

AU - Tomida, Shuta

AU - Yamamoto, Hiromasa

AU - Asano, Hiroaki

AU - Sou, Junichi

AU - Tsukuda, Kazunori

AU - Nagasaka, Takeshi

AU - Fujiwara, Toshiyoshi

AU - Toyooka, Shinichi

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti-human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti-HER2 drug presently available for gastric cancer. In this study, we propose novel treatment options for patients with HER2-positive gastric cancer. First, we determined the molecular profiles of 12 gastric cancer cell lines, and examined the antitumor effect of the pan-HER inhibitors afatinib and neratinib in those cell lines. Additionally, we analyzed HER2 alteration in 123 primary gastric cancers resected from Japanese patients to clarify possible candidates with the potential to respond to these drugs. In the drug sensitivity analysis, both afatinib and neratinib produced an antitumor effect in most of the HER2-amplified cell lines. However, some cells were not sensitive to the drugs. When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors. A combination therapy consisting of pan-HER inhibitors and an IGF-1R inhibitor, picropodophyllin, showed a notable synergistic effect. Among 123 clinical samples, we found 19 cases of HER2 amplification and three cases of oncogenic mutations. In conclusion, afatinib and neratinib are promising therapeutic options for the treatment of HER2-amplified gastric cancer. In addition to HER2 amplification, IGFBP7 might be a biomarker of sensitivity to these drugs, and IGF-1R-targeting therapy can overcome drug insensitiveness in HER2-amplified gastric cancer.

AB - Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti-human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti-HER2 drug presently available for gastric cancer. In this study, we propose novel treatment options for patients with HER2-positive gastric cancer. First, we determined the molecular profiles of 12 gastric cancer cell lines, and examined the antitumor effect of the pan-HER inhibitors afatinib and neratinib in those cell lines. Additionally, we analyzed HER2 alteration in 123 primary gastric cancers resected from Japanese patients to clarify possible candidates with the potential to respond to these drugs. In the drug sensitivity analysis, both afatinib and neratinib produced an antitumor effect in most of the HER2-amplified cell lines. However, some cells were not sensitive to the drugs. When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors. A combination therapy consisting of pan-HER inhibitors and an IGF-1R inhibitor, picropodophyllin, showed a notable synergistic effect. Among 123 clinical samples, we found 19 cases of HER2 amplification and three cases of oncogenic mutations. In conclusion, afatinib and neratinib are promising therapeutic options for the treatment of HER2-amplified gastric cancer. In addition to HER2 amplification, IGFBP7 might be a biomarker of sensitivity to these drugs, and IGF-1R-targeting therapy can overcome drug insensitiveness in HER2-amplified gastric cancer.

KW - Afatinib

KW - gastric cancer

KW - HER2

KW - IGFBP7

KW - neratinib

UR - http://www.scopus.com/inward/record.url?scp=85044261091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044261091&partnerID=8YFLogxK

U2 - 10.1111/cas.13546

DO - 10.1111/cas.13546

M3 - Article

VL - 109

SP - 1166

EP - 1176

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 4

ER -